069620 — Daewoong Pharma Cashflow Statement

0.000.00%

Last trade - 00:00

HealthcareAdventurousMid CapHigh Flyer

Annual cashflow statement for Daewoong Pharma, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Net Income/Starting Line	24,148	30,257	39,163	120,003	23,347
Depreciation
Amortisation
Non-Cash Items	20,655	13,038	27,049	16,450	122,489
Unusual Items
Equity in Net Earnings/Losses
Other Non-Cash Items
Changes in Working Capital	16,636	-42,865	13,650	-43,145	-142,481
Change in Accounts Receivable
Change in Inventories
Change in Other Assets
Change in Accounts Payable
Change in Other Liabilities
Other Operating Cash Flow
Cash from Operating Activities	100,981	39,994	118,215	136,009	51,492
Capital Expenditures	-26,486	-29,088	-65,161	-109,338	-155,145
Purchase of Fixed Assets
Other Investing Cash Flow Items	-100,665	-58,595	-41,710	-56,283	-110,306
Sale of Fixed Assets
Sale/Maturity of Investment
Change in Net Investments
Purchase of Investments
Sale of Intangible Assets
Change in Net Intangibles
Other Investing Cash Flow
Cash from Investing Activities	-127,152	-87,683	-106,872	-165,621	-265,451
Financing Cash Flow Items	-4,796	18,740	25,050	0	4,693
Other Financing Cash Flow
Total Cash Dividends Paid
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities	66,587	50,224	15,517	39,218	200,621
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash	40,205	3,608	27,044	8,555	-8,556